Gleevec revenue trends
In 3Q17, Novartis’s (NVS) Gleevec generated revenues of $445 million, which was ~47% lower YoY (year-over-year) and ~12% lower QoQ (quarter-over-quarter). Due to stiff competition from the generic imatinib across major markets, Gleevec’s revenues continued to decline.
In 3Q17, other important drugs for chronic lymphocytic leukemia included Gilead Sciences’ (GILD) Zydelig, Pfizer’s Imbruvica, and Roche’s Gazyva, which reported revenues of ~$40 million, ~$878 million, and $~69 million, respectively.
Sandostatin revenue trends
In 3Q17, Sandostatin generated revenues of $402 million, which was ~3% lower YoY. In 3Q17, Sandostatin’s QoQ revenues remained flat. Increased market competition primarily attributed to this modest revenue decline in 3Q17.
Sandostatin (octreotide acetate) is used for the treatment of acromegaly and severe diarrhea and flushing episodes.
Afinitor, Votubia revenue trends
In 3Q17, Afinitor generated revenues of ~$389 million, which was ~1% lower YoY but 1% higher QoQ.
Afinitor (everolimus) has been approved for the use in advanced breast cancer, advanced kidney cancer, Advanced Pancreatic Neuroendocrine Tumor (or NET), Renal Angiomyolipoma with Tuberous Sclerosis Complex, and subependymal giant cell astrocytoma (or SEGA) with Tuberous Sclerosis Complex.
Afinitor’s peer drugs for advanced kidney cancer include Bristol-Myers Squibb’s (BMY) Opdivo and Exelixis’s (EXEL) Cabometyx. In 3Q17, Opdivo and Cabometyx reported revenues of $1.26 billion and $90 million, respectively.
Exjade, Jadenu revenue trends
In 3Q17, Exjade generated revenues of $264 million, which was ~9% higher YoY but 1% lower QoQ. The steady uptake of Exjade film-coated tablets primarily attributed to this revenue growth in 3Q17.
Exjade (deferasirox) is used as a treatment for iron overload due to blood transfusions in individuals at least 12 years old.
Notably, the First Trust Value Line Dividend Index Fund (FVD) has ~0.51% of its total portfolio holdings in NVS.